Americo Cicchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4614073/publications.pdf

Version: 2024-02-01

93 papers 1,809 citations

304743 22 h-index 302126 39 g-index

95 all docs 95
docs citations

95 times ranked 2741 citing authors

#	Article	IF	CITATIONS
1	Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4085-4091.	3.2	185
2	The Jefferson Scale of Physician Empathy: Preliminary Psychometrics and Group Comparisons in Italian Physicians. Academic Medicine, 2009, 84, 1198-1202.	1.6	132
3	Comparisons of American, Israeli, Italian and Mexican physicians and nurses on the total and factor scores of the Jefferson scale of attitudes toward physician–nurse collaborative relationships. International Journal of Nursing Studies, 2003, 40, 427-435.	5.6	129
4	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	7.3	97
5	The use of "harmonic scalpel―versus "knot tying―for conventional "open―thyroidectomy: results c a prospective randomized study. Langenbeck's Archives of Surgery, 2008, 393, 627-631.	of _{1.9}	74
6	Physician social capital and the reported adoption of evidence-based medicine: Exploring the role of structural holes. Social Science and Medicine, 2011, 72, 798-805.	3.8	63
7	Factors associated with health-related quality of life: the role of social relationships among the elderly in an Italian region. Public Health, 2008, 122, 784-793.	2.9	54
8	The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics, 2019, 22, 8-15.	1.0	49
9	Exploring "patient-centered―hospitals: a systematic review to understand change. BMC Health Services Research, 2017, 17, 364.	2.2	48
10	MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2015, 31, 210-213.	0.5	44
11	Dynamic analysis of interhospital collaboration and competition: Empirical evidence from an Italian regional health system. Health Policy, 2012, 105, 273-281.	3.0	41
12	Hospital managers' need for information in decision-making – An interview study in nine European countries. Health Policy, 2015, 119, 1424-1432.	3.0	41
13	Health technology assessment in Italy. International Journal of Technology Assessment in Health Care, 2009, 25, 127-133.	0.5	37
14	GUIDING PRINCIPLES FOR GOOD PRACTICES IN HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT UNITS. International Journal of Technology Assessment in Health Care, 2015, 31, 457-465.	0.5	36
15	NutriCatt protocol in the Enhanced Recovery After Surgery (ERAS) program for colorectal surgery: The nutritional support improves clinical and cost-effectiveness outcomes. Nutrition, 2018, 50, 74-81.	2.4	35
16	Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. European Review for Medical and Pharmacological Sciences, 2019, 23, 2986-3000.	0.7	32
17	Unfolding similarity in interphysician networks: the impact of institutional and professional homophily. BMC Health Services Research, 2015, 15, 92.	2.2	31
18	Economic Assessment of an Anti-HCV Screening Program in Italy. Value in Health, 2013, 16, 965-972.	0.3	28

#	Article	IF	CITATIONS
19	Physicians' propensity to collaborate and their attitude towards EBM: A cross-sectional study. BMC Health Services Research, 2011, 11, 172.	2.2	27
20	Impact of SARS-CoV-2 on Provided Healthcare. Evidence From the Emergency Phase in Italy. Frontiers in Public Health, 2020, 8, 583583.	2.7	26
21	Modeling costâ€effectiveness and health gains of a "universal†versus "prioritized†hepatitis C virus treatment policy in a real†life cohort. Hepatology, 2017, 66, 1814-1825.	7.3	25
22	Health technology assessment agencies: An international overview of organizational aspects. International Journal of Technology Assessment in Health Care, 2007, 23, 414-424.	0.5	23
23	Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy. Journal of Medical Economics, 2018, 21, 902-911.	2.1	23
24	Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults. Clinical Drug Investigation, 2013, 33, 343-349.	2.2	22
25	"Us and Them― a social network analysis of physicians' professional networks and their attitudes towards EBM. BMC Health Services Research, 2013, 13, 429.	2.2	22
26	Assessing hospital performance indicators. What dimensions? Evidence from an umbrella review. BMC Health Services Research, 2020, 20, 1038.	2.2	22
27	The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. Frontiers in Pharmacology, 2021, 12, 699466.	3.5	22
28	Relating price determination to disease prevalence. BMJ: British Medical Journal, 2010, 341, c4615-c4615.	2.3	22
29	Use of robotâ€specific resources and operating room times: the case of Telelap Alfâ€X robotic hysterectomy. International Journal of Medical Robotics and Computer Assisted Surgery, 2016, 12, 613-619.	2.3	19
30	Looking good or doing better? Patterns of decoupling in the implementation of clinical directorates. Health Care Management Review, 2014, 39, 111-123.	1.4	18
31	Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. Journal of Critical Care, 2019, 50, 169-176.	2.2	18
32	The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond. Diabetes Therapy, 2021, 12, 2311-2327.	2.5	18
33	Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. Blood Transfusion, 2016, 14, 287-386.	0.4	17
34	Cost-consequence analysis of influenza vaccination among the staff of a large teaching hospital in Rome, Italy: A pilot study. PLoS ONE, 2019, 14, e0225326.	2.5	16
35	Hospital restructuring and physician job satisfaction: An empirical study. Health Policy, 2014, 114, 118-127.	3.0	15
36	Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. Applied Health Economics and Health Policy, 2018, 16, 711-722.	2.1	15

#	Article	IF	CITATIONS
37	Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review. Value in Health, $2015,18,709$ - $720.$	0.3	14
38	Professional networks and the alignment of individual perceptions about medical innovation. Health Care Management Review, 2018, 43, 92-103.	1.4	14
39	Extending influenza vaccination to individuals aged 50–64: A budget impact analysis. International Journal of Technology Assessment in Health Care, 2010, 26, 288-293.	0.5	13
40	THE HARMONIC STUDY: COST-EFFECTIVENESS EVALUATION OF THE USE OF THE ULTRASONIC SCALPEL IN TOTAL THYROIDECTOMY. International Journal of Technology Assessment in Health Care, 2012, 28, 259-264.	0.5	13
41	Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system. Blood Transfusion, 2018, 16, 483-489.	0.4	13
42	Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing. Blood Transfusion, 2013, 11 Suppl 4, s138-47.	0.4	13
43	The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy, 2011, 102, 72-80.	3.0	11
44	TOWARD A CONTINGENCY MODEL FOR HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT: EVIDENCE FROM ADHOPHTA PROJECT. International Journal of Technology Assessment in Health Care, 2018, 34, 205-211.	0.5	11
45	Hospital contextual factors affecting the implementation of health technologies: a systematic review. BMC Health Services Research, 2021, 21, 407.	2.2	11
46	Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence. Health Policy, 2022, 126, 337-345.	3.0	11
47	COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. International Journal of Technology Assessment in Health Care, 2016, 32, 233-240.	0.5	10
48	Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. Value in Health, 2018, 21, 783-791.	0.3	10
49	Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Applied Health Economics and Health Policy, 2017, 15, 479-490.	2.1	9
50	Back to the future: a new topical approach for mild-to-moderate psoriasis. Italian Journal of Dermatology and Venereology, 2018, 153, 375-382.	0.2	9
51	A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems. Frontiers in Medical Technology, 0, 4, .	2.5	9
52	Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. Digestive and Liver Disease, 2015, 47, 351-355.	0.9	8
53	Translating strategy into practice: A tool to understand organizational change in a Spanish university hospital. An in-depth analysis in Hospital Clinic. International Journal of Healthcare Management, 2020, 13, 142-155.	2.0	8
54	Return on Investment (ROI) and Development of a Workplace Disability Management Program in a Hospitalâ€"A Pilot Evaluation Study. International Journal of Environmental Research and Public Health, 2020, 17, 8084.	2.6	8

#	Article	IF	CITATIONS
55	Estimating the fiscal impact of three vaccination strategies in Italy. International Journal of Technology Assessment in Health Care, 2020, 36, 133-138.	0.5	8
56	AGING AND HEALTH TECHNOLOGY ASSESSMENT: AN IDEA WHOSE TIME HAS COME. International Journal of Technology Assessment in Health Care, 2018, 34, 442-446.	0.5	7
57	Economic evaluation of Zepatier for the management of HCV in the Italian scenario. European Journal of Health Economics, 2018, 19, 1365-1374.	2.8	6
58	Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 363-374.	1.4	6
59	Costâ€Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 947-955.	3.4	5
60	Linking the Price of Cancer Drug Treatments to Their Clinical Value. Clinical Drug Investigation, 2016, 36, 579-589.	2.2	5
61	Preventing mobility disability in Europe: a health economics perspective from the SPRINTT study. Aging Clinical and Experimental Research, 2017, 29, 75-79.	2.9	5
62	SHARING AND COLLECTING HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT REPORTS INTERNATIONALLY: IS AN EXTENSIVE PARTICIPATION OF STAKEHOLDERS REALISTIC?. International Journal of Technology Assessment in Health Care, 2018, 34, 527-534.	0.5	5
63	Dealing with COVID-19 Epidemic in Italy: Responses from Regional Organizational Models during the First Phase of the Epidemic. International Journal of Environmental Research and Public Health, 2021, 18, 5008.	2.6	5
64	HPV Vaccination in Women Treated for Cervical Intraepithelial Neoplasia: A Budget Impact Analysis. Vaccines, 2021, 9, 816.	4.4	4
65	Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease. European Journal of Health Economics, 2023, 24, 247-277.	2.8	4
66	Valutazione economica di un programma di screening anti-HCV in Italia. Pharmacoeconomics Italian Research Articles, 2011, 13, 81-99.	0.2	3
67	Economic evaluation of colorectal cancer screening programs: Affordability for the health service. Journal of Medical Screening, 2020, 27, 186-193.	2.3	3
68	Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015–2018. Journal of Oncology Pharmacy Practice, 2021, 27, 877-886.	0.9	3
69	Impact of technology overlapping: A case study on colorectal cancer screening. Technology and Health Care, 2010, 18, 303-315.	1.2	2
70	Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory. Quality and Quantity, 2017, 51, 1261-1276.	3.7	2
71	Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals. Eurasian Business Review, 2019, 9, 89-101.	4.2	2
72	Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy. Global & Regional Health Technology Assessment, 2020, 7, 101-108.	0.1	2

#	Article	IF	CITATIONS
73	Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs. Global & Regional Health Technology Assessment, 2020, 7, 26-32.	0.1	2
74	Reply to G. Dionigi's letter: energy based devices and recurrent laryngeal nerve injury: the need for safer instruments. Langenbeck's Archives of Surgery, 2009, 394, 583-584.	1.9	1
75	Lo studio HARMONIC: valutazione costo-efficacia dell'uso del bisturi a ultrasuoni negli interventi di tiroidectomia totale. Pharmacoeconomics Italian Research Articles, 2010, 12, 143-155.	0.2	1
76	Assessing social and economic impact of subcutaneous mAbs in oncology. Global & Regional Health Technology Assessment, 2018, 2018, 228424031875787.	0.1	1
77	SIR-Spheres < sup > \hat{A}^{\otimes} < /sup > Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer. Global & Regional Health Technology Assessment, 2019, 2019, 228424031984744.	0.1	1
78	OP71 Understanding Hospitals' Performance Variability: Conceptual Framework. International Journal of Technology Assessment in Health Care, 2019, 35, 17-18.	0.5	1
79	Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population. Global & Regional Health Technology Assessment, 0, 8, 105-113.	0.1	1
80	Hospital reorganization and its effects on physicians' network churn: The role of past ties. Social Science and Medicine, 2021, 286, 113885.	3.8	1
81	"Between Hierarchies & Markets, The logic and the limits of network forms of organization―By Grahame F. Thompson, Oxford University Press, 2003. Journal of Management and Governance, 2005, 9, 199-203.	4.1	0
82	L'utilizzo di modelli decisionali per le valutazioni economiche dei farmaci in Italia: stato dell'arte e prospettive future. Pharmacoeconomics Italian Research Articles, 2007, 9, 59-73.	0.2	0
83	Valutazione costo-efficacia del percorso dei pazienti a rischio di epatite B sottoposti a test anti-HBV. Pharmacoeconomics Italian Research Articles, 2009, 11, 105-119.	0.2	0
84	Valutazione dei costi delle infezioni nosocomiali da Escherichia coli. Pharmacoeconomics Italian Research Articles, 2010, 12, 81-90.	0.2	0
85	La definizione di "farmaco innovativo―nella prospettiva dell'Health Technology Assessment. Pharmacoeconomics Italian Research Articles, 2012, 14, 65-68.	0.2	0
86	Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?. Economic Analysis and Policy, 2017, 55, 47-56.	6.6	0
87	PP39 Health Technology Assessment And Aging: Moving Evidence To Action. International Journal of Technology Assessment in Health Care, 2018, 34, 80-80.	0.5	0
88	Professional Networks and the Alignment of Individual Perceptions toward Medical Innovation. Proceedings - Academy of Management, 2015, 2015, 13161.	0.1	0
89	Professional Networks and the AdoptionÂof Medical Technologies: An Empirical Study on Robotic Surgery. , 2018, , 143-163.		0
90	"When the Time Comes": Exploring Temporal Differences in the Adoption of Medical Innovation. Studi Organizzativi, 2019, , 62-87.	0.3	0

AMERICO CICCHETTI

#	Article	IF	CITATIONS
91	PP469 From Theory To Practice: Which Value Framework Is Applied For Onco-Hematology Therapies In Italy? A 5-year Retrospective Analysis. International Journal of Technology Assessment in Health Care, 2020, 36, 37-37.	0.5	O
92	PP399 Analysis Of Referral Patterns To Specialized Centers In Idiopathic Pulmonary Fibrosis To Define A New Regional Care Pathway. International Journal of Technology Assessment in Health Care, 2020, 36, 33-33.	0.5	0
93	A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer. Global & Regional Health Technology Assessment, 2020, $7,1$ -8.	0.1	0